DNC Biotechnology Selected for the ‘Super-Gap Startup 1000+ Project’ by the Ministry of SMEs and Startups

DNC Biotechnology (CEO Seong-Soo Park), a next-generation urine diagnostic solutions and home healthcare specialist, announced on the 26th that it has been selected as a final candidate in the Biohealth Medical Device and Digital Healthcare category of the ‘2025 Super-Gap Startup Nurturing Project (DIPS 1000+)’ organized by the Ministry of SMEs and Startups.

As a selected participant in the ‘Super-Gap Startup 1000+ Project,’ DNC Biotechnology will receive direct funding of up to 1.1 billion KRW, including a maximum of 600 million KRW for commercialization over the next three years and up to 500 million KRW in R&D funding for up to two years, based on company-specific evaluations. Additionally, the company will benefit from policy-linked support in areas such as financing, guarantees, and exports.

Furthermore, the designated supervising institution for each sector will provide close support throughout the entire growth process, from product and service enhancement to identifying demand sources and attracting investments.

DNC Biotechnology’s next-generation urine diagnostic solution for medical institutions and urine-based home healthcare system, selected for the ‘Super-Gap Startup 1000+ Project,’ enhances convenience and stability in the diagnostic testing process. This reduces the workload of medical personnel while improving accessibility and connectivity with healthcare providers for individual users.

Moreover, by utilizing life-log data and basic diagnostic data, the solution enables preventive healthcare and chronic disease management. Notably, its core optical biosensor technology has obtained New Excellent Technology (NET) certification, demonstrating the technological expertise and reliability of the solution.

Seong-Soo Park, CEO of DNC Biotechnology, stated, “Through our selection in the Super-Gap Startup 1000+ Project, the technological excellence, innovation, and business potential of our next-generation urine diagnostic solution have been recognized. We will continue to advance our services through ongoing research and technological innovation, strengthen our global competitiveness, and contribute to the advancement of public health worldwide as a leading global biohealth medical device company.”